GE Healthcare's Sofie Deal to Vertically Integrate Radiopharma Portfolio, Needham Says

MT newswire2026/10/05 19:04

03:04 PM EDT, 10/05/2026 (MT Newswires) -- GE Healthcare Technologies' (GEHC) planned $945 million acquisition of Sofie Biosciences should enable it to vertically integrate its radiopharmaceuticals portfolio and adds a phase 3 asset to its pipeline, Needham said in a Monday note. With the acquisition, GEHC should be able to integrate production and distribution of its radiopharmaceuticals portfolio. Sofie's distribution network includes 15 CMO sites across the US with two coming soon, Needham analysts said, citing the firm's website. The acquisition also brings US rights to FAPI-74, Sofie's F18 fibroblast activation protein inhibitor asset that is in phase 3 and to which GE Healthcare already owns the rights outside the US. With trials for the drug estimated to complete in H2 of 2027, the analysts said they expect potential commercialization in 2029 at the earliest. Needham reiterated its buy rating on the company, with a $93 price target. Shares of GE Healthcare were up more than 2% in Monday afternoon trading. Price: 65.61, Change: +1.32, Percent Change: +2.05

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"

华尔街见闻•2026/10/11 01:57

A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year

BeInCrypto•2026/10/10 22:48

The number of stablecoin holders on the Solana chain has surpassed 14 million.

AiCoin•2026/10/10 21:35

Cathie Wood’s ARK Sells Bitcoin ETF, SpaceX and Robinhood Shares in Portfolio Shift

CoinEdition•2026/10/10 17:39